Michael Knauer, Christine Gruber, Otto Dietze, Richard Greil, Herbert Stöger, Margaretha Rudas, Zsuzsanna Bagó-Horváth, Brigitte Mlineritsch, W. Kwasny, Christian Singer, Peter Dubsky, R. Jakesz, Florian Fitzal, Günther Steger, Rupert Bartsch, Martin Filipits, Christian Fesl, Michael Gnant,
... differences in benefit from adjuvant Tamoxifen (Tam) and Anastrozol (Ana) for these histologic subtypes. Patients and Methods: ... The 3-year OS hazard ratio (HR) for Anastrozol versus Tamoxifen in ILC (n=694) was 0. ... Discussion: The magnitude of survival benefit from adjuvant Anastrozol vs. Tamoxifen varies by histology in this large ... Filipits, Christian Fesl, Michael Gnant. Survival advantage of anastrozol compared to tamoxifen for lobular breast cancer in ...
Tópico(s): Breast Cancer Treatment Studies
2015 - American Association for Cancer Research | Cancer Research
Produção Nacional
Revisado por pares
André Deeke Sasse, Emma Chen Sasse,
... com dados nacionais sobre a possível incorporação do anastrozol como terapia adjuvante hormonal no câncer de mama ... câncer de mama, em mulheres pós-menopausa, do anastrozol versus tamoxifeno em três perspectivas: do paciente, de ... benefícios encontrados para 25 anos de seguimento, o anastrozol, em relação ao tamoxifeno, resultou numa estimativa de ... pacientes. CONCLUSÃO: O benefício encontrado no uso do anastrozol adjuvante em pacientes com câncer de mama operado ...
Tópico(s): Economic and Financial Impacts of Cancer
2009 - Brazilian Medical Association | Revista da Associação Médica Brasileira
Matteo Lambertini, Giulia Viglietti, Evandro de Azambuja,
... combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast ... combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast ... combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast ...
Tópico(s): Estrogen and related hormone effects
2018 - Elsevier BV | ESMO Open
Turgut Kaçan, Çağlar Yıldız, Selen Baloğlu Kaçan, M. Seker, Hatice Özer, Ali Çetin,
... Everolimus (1,5 mg/kg/d, p. o.), Anastrozol (0,004 mg/d, p. o.), oder Kochsalzlösung ( ... CD117 und Bax durchgeführt. Ergebnisse Die Gabe von Anastrozol wie auch von Everolimus verringerte die Endometriosewerte. Nach der Behandlung mit Anastrozol wurde aber ein signifikanter Rückgang ovarieller Follikel vermerkt, ...
Tópico(s): Uterine Myomas and Treatments
2017 - Thieme Medical Publishers (Germany) | Geburtshilfe und Frauenheilkunde
Produção Nacional
Revisado por pares
Sandro Garcia Hilário, Nilo Bozzini, Rodrigo Borsari, Edmund Chada Baracat,
... 35 years of age, with symptomatic uterine leiomyoma.Anastrozol, 1 mg/day for 12 weeks.Measurement of ... estradiol during use of the medication were observed.Anastrozol proved to be effective in reducing the volume ...
Tópico(s): Gynecological conditions and treatments
2008 - Elsevier BV | Fertility and Sterility
Juliana Coral-Casas, Andrés Ricaurte-Fajardo, Samuel McCormick, Ivan Baracaldo, C A Jimenez, Javier Alfonso Aguilar Mejía,
... pharmacovigilance.Sindrome de vasoconstriccion cerebral reversible asociado a anastrozol: una causa inusual de alto impacto.Introduccion. El ... tamoxifeno; por presentar urticaria, se escalono tratamiento con anastrozol. Ingreso por cefalea de tipo trueno, afasia anterior ... SVCR mas HSA esta asociado al uso de anastrozol. Hasta el momento no hay casos descritos de ...
Tópico(s): Pharmacological Effects and Toxicity Studies
2019 - Viguera Publishers | Revista de Neurología
Mădălina Drăgănescu, Codruţa Carmocan,
... controlateral cât şi durata suprvieţuirii.Inhibitorii de aromatazã: Anastrozol, Letrozol, Exemestan se folosesc numai în post menopauzã. ...
Tópico(s): Male Breast Health Studies
2017 - | Chirurgia
Manuel Ruíz‐Borrego, M. Martín Jiménez, A. Ruíz, Aña Lluch, Manuel Ramos, Josefina Cruz Jurado, José Manuel Baena-Cañada, Beatriz Cirauqui, Álvaro Rodríguez-Lescure, Emilio Alba, Noelia Martínez-Jáñez, Montserrat Muñoz, Silvia Antolín, I. Álvarez López, Sonia Del Barco, Laura García‐Estévez, José Ignacio Chacón, Antonio Antón Torres, Eva Carrasco,
Background: F is a selective estrogen receptor degrader for HR+ advanced breast cancer patients (pts). We designed this trial to compare A vs. A in combination with F (A+F) to address the hypothesis that a complete estrogen blockade can prevent resistance to aromatase inhibitors in the adjuvant setting. Methods: This was a multicenter, open label, phase III study in which HR+/HER2- EBC postmenopausal pts were randomized 1:1 to A for 5 years (y) or A+F (A concurrently with F 250mg/4 weeks for 3y followed ...
Tópico(s): Breast Cancer Treatment Studies
2017 - Elsevier BV | Annals of Oncology
Michael Gnant, Brigitte Mlineritsch, Herbert Stoeger, G. Luschin-Ebengreuth, Michael Knauer, Martin Moik, R. Jakesz, Michael Seifert, Susanne Taucher, Vesna Bjelic‐Radisic, Marija Balić, Holger Eidtmann, W. Eiermann, Guenther G. Steger, W. Kwasny, Peter Dubsky, U Selim, Florian Fitzal, Gerhard Hochreiner, V. Wette, P. Sevelda, F. Ploner, Rupert Bartsch, Christian Fesl, Richard Greil,
ABSTRACT These final results from ABCSG-12 confirm that twice-yearly ZOL safely enhances the efficacy of adjuvant endocrine therapy. Tamoxifen together with Goserelin for now remains the endocrine standard of care. In general, overall survival of more than 95% at 8 years' median follow-up supports the efficacy of endocrine-only regimens in this premenopausal patient population. Background Zoledronic acid (ZOL) plus adjuvant endocrine therapy significantly improved disease-free survival (DFS) at 48- and 62- ...
Tópico(s): Prostate Cancer Treatment and Research
2014 - Elsevier BV | Annals of Oncology
Fabrice Krier, Raphaël Riva, Sylvie Defrère, Mélanie Mestdagt, Anne Van Langendonckt, Pierre Drion, Jean‐Paul Dehoux, J. Donnez, Jean‐Michel Foidart, Christine Jérôme, Brigitte Évrard,
Local treatment using drug loaded implants allows decreasing seric concentrations of the active ingredient with the purpose of limiting side effects and reaching perfect observance. Nowadays, some diseases are already treated with implants, but generally, by subcutaneous or intra vaginal implantation. In this work, a new implant device dedicated to the intra-peritoneal cavity was developed. For this purpose, a core-mem-brane polymer implant was selected. We propose an original method to determine ...
Tópico(s): Anesthesia and Pain Management
2014 - Elsevier BV | Journal of Drug Delivery Science and Technology
Fıkret Erdemır, Doğan Atılgan, Fatma Markoç, Özgür Boztepe, B. Suha-Parlaktas, Şafak Şahin,
... 11), una dieta alta en grasas junto con anastrozol. A las 10 semanas se obtu-vieron los ...
Tópico(s): Sexual Differentiation and Disorders
2012 - Elsevier BV | Actas Urológicas Españolas (English Edition)
Martin Koskas, Nathalie Chabbert‐Buffet, S. Douvier, Cyrille Huchon, E. Paganelli, Jean Derrien,
... reduce leiomyoma volume and provide less hot flushes. Anastrozol is associated with reduction in leiomyomata volume, pain ...
Tópico(s): Gynecological conditions and treatments
2011 - Elsevier BV | Journal de gynécologie, obstétrique et biologie de la reproduction. Supplément/Journal de gynécologie obstétrique et biologie de la reproduction
Produção Nacional
Revisado por pares
André Deeke Sasse, Emma Chen Sasse,
Carry out an economic analysis of the incorporation of anastrozole as adjuvant hormone therapy in postmenopausal women with breast cancer in a Brazilian setting.The cost-effectiveness estimate comparing anastrozole to tamoxifen was made from the perspectives of the patient, private health insurance, and government. A Markov model was designed based on data from ATAC trial after 100 months follow-up in a hypothetical cohort of 1000 postmenopausal women in Brazil, using outcomes projections for a ...
Tópico(s): Public Health in Brazil
2009 - Brazilian Medical Association | Revista da Associação Médica Brasileira
Yoshiya Horimoto, Mitsue Saito, Fujio Kasumi,
... zu bestätigen.Von 329 Patienten, die Aromatasehemmer (239 Anastrozol und 90 Exemestan) einnahmen, litten 27% unter Arthralgie. ...
Tópico(s): Endometrial and Cervical Cancer Treatments
2009 - Karger Publishers | Breast Care
Július Hodosy, Peter Celec, Daniela Ostatníková, Marieta Cagánová, Zdeněk Putz, Peter Baláž, Matúš Kúdela,
Abstract Androgens are known to affect cognitive functions via organizational and activational effects. It is unknown whether the effects are mediated via the androgen receptor or after conversion to estradiol with aromatase via estrogen receptors. The aim of our study was to find out whether testosterone affects spatial memory directly or through its metabolite estradiol. Rats were treated with testosterone; with testosterone and the aromatase blocker anastrozole or saline. An 8 radial arm maze ...
Tópico(s): Memory and Neural Mechanisms
2009 - De Gruyter Open | Open Life Sciences
Andreas D. Ebert, Julia Bartley, Matthias David,
... Thus, specific aromatase inhibitors (e.g. Letrozol/Femara®, Anastrozol/Arimidex® or Exemestan/Aromasin®) or selective COX-2 ...
Tópico(s): Endometrial and Cervical Cancer Treatments
2005 - Elsevier BV | European Journal of Obstetrics & Gynecology and Reproductive Biology
Semiglazov Vf, Semiglazov Vf, В Г Иванов, А. А. Божок, E.K. Ziltsova, Р. М. Палтуев, Г А Дашян, A. Kletzel, Э. Э. Топузов, Lev M. Berstein,
... Tendency to more BCS took place in the anastrozol arm that in the CT arm ( 37.9 % ...
Tópico(s): Breast Cancer Treatment Studies
2004 - Lippincott Williams & Wilkins | Journal of Clinical Oncology
Semiglazov Vf, Vladimir Semiglazov, В Г Иванов, А. А. Божок, E.K. Ziltsova, Р. М. Палтуев, Г А Дашян, A. Kletzel, Э. Э. Топузов, Lev M. Berstein,
... Tendency to more BCS took place in the anastrozol arm that in the CT arm ( 37.9 % ...
Tópico(s): Breast Cancer Treatment Studies
2004 - Lippincott Williams & Wilkins | Journal of Clinical Oncology
A. Ebert, Julia Bartley, Matthias David, Karl-Werner Schweppe,
... therapeutische Targets angesehen. Spezifische Aromatase-Inhibitoren (wie Letrozol, Anastrozol oder Exemestan) oder selektive COX-2-Blocker (z. ...
Tópico(s): Estrogen and related hormone effects
2003 - Johann Ambrosius Barth Verlag | Zentralblatt für Gynäkologie
J. Huober, U Wagner, D. Wallwiener,
... Vordergrund. Aufgrund der aktuellen Datenlage stellen Letrozol und Anastrozol nach ihrer Zulassung jetzt reale Alternativen zum bisherigen ... dar. Erste Ergebnisse zu den Studien mit Letrozol, Anastrozol und Exemestan in der neoadjuvanten und adjuvanten Situation ...
Tópico(s): Advanced Breast Cancer Therapies
2002 - Thieme Medical Publishers (Germany) | Geburtshilfe und Frauenheilkunde
Produção Nacional
Revisado por pares
Herlem Silva Rodrigues, Railson Pereira Souza, Rayran Walter Ramos de Sousa, Layane Carneiro Alves Pereira, Renata Rodrigues de Oliveira Castelo Branco, Pedro Henrique Fernandes Paiva Silveira, Maria Helena Rodrigues Mesquita Britto,
... perfazendo um total de 360.703 fármacos. O anastrozol foi o mais prescrito (51,85%) e os ... não apresentaram nenhum tipo de interação foram o anastrozol e o dietilestilbestrol. Dos agentes farmacológicos que mais ...
Tópico(s): Public Health in Brazil
2020 - Grupo de Pesquisa Metodologias em Ensino e Aprendizagem em Ciências | Research Society and Development
A. Krause, Wolfgang Janni, Toralf Reimer, B. Gerber,
648 Purpose: To compare the effects of switching from adjuvant Tam treatment to Ana in postmenopausal breast cancer women with abnormal vaginal bleedings during Tam treatment and histologically proven benign endometrial pathology. Patients & Methods: 110 postmenopausal women who had received Tam 20 mg/day (312 months, £48 months) and developed abnormal vaginal bleeding were subjected to hysteroscopy as well as dilation and curettage (D&C). Thereafter they were randomized to continue Tam treatment (n=88) ...
Tópico(s): Endometrial and Cervical Cancer Treatments
2005 - Lippincott Williams & Wilkins | Journal of Clinical Oncology
Vito Amoroso, Fausto Petrelli, Rebecca Pedersini, Edda Simoncini, Philippe Clézardin, Sandro Barni, Alfredo Berruti,
... combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast ...
Tópico(s): Medical Imaging Techniques and Applications
2015 - Future Medicine | Future Oncology
MW Beckmann, MP Lux, PA Fasching,
... or in Combination (ATAC)-Studie konnte zeigen, dass Anastrozol in der adjuvanten Behandlung postmenopausaler Frauen mit Hormonrezeptor- ... ist als Tamoxifen. Jedoch ist die Therapie mit Anastrozol mit einem Rückgang der Knochendichte und einer höheren ... zeigen, dass sich die Frakturrate nach Therapie im Anastrozol-Arm auf das Niveau des Tamoxifen-Arms angleicht. ...
Tópico(s): HER2/EGFR in Cancer Research
2008 - Georg Thieme Verlag | Senologie - Zeitschrift für Mammadiagnostik und -therapie
MW Beckmann, MP Lux, PA Fasching,
... or in Combination (ATAC)-Studie konnte zeigen, dass Anastrozol in der adjuvanten Behandlung postmenopausaler Frauen mit HR- ... ist als Tamoxifen. Jedoch ist die Therapie mit Anastrozol mit einer höheren Frakturrate während der Behandlungsphase assoziiert. ...
Tópico(s): Colorectal Cancer Treatments and Studies
2008 - Thieme Medical Publishers (Germany) | Geburtshilfe und Frauenheilkunde
C Hanusch, K. Greven, S Zaun, S. Paepke,
Zielsetzung: Die Effektivität von Anastrozol bei HR-positiven postmenopausalen Frauen mit frühem Mammakarzinom wurde durch Studien gut belegt. Ziel dieser Untersuchung war es, Daten zu ...
Tópico(s): Estrogen and related hormone effects
2008 - Georg Thieme Verlag | Senologie - Zeitschrift für Mammadiagnostik und -therapie
... to reduce leiomyoma volume and provide less hotflushes. Anastrozol is associated with reduction in leiomyomata volume, pain ...
Tópico(s): Gynecological conditions and treatments
2013 - Elsevier BV | La Presse Médicale
... longer than the referred 3.5 years taking anastrozol. We would also like to comment that the ...
Tópico(s): Urological Disorders and Treatments
2013 - Springer Science+Business Media | Journal of General Internal Medicine
M. Ziller, W. Holzhauer, Volker Ziller, U Wagner, P. Hadji,
... 4 years have been reported. No data on Anastrozol has yet been reported. The aim of this ...
Tópico(s): Estrogen and related hormone effects
2007 - Georg Thieme Verlag | Senologie - Zeitschrift für Mammadiagnostik und -therapie
Maman Abdurahman, Kiki A. Rizki,
... serum baik pada pasien KPD pascamenopause yang diberikan anastrozol dan tamoksifen di Rumah Sakit Dr. Hasan Sadikin ... kadar β-CrossLap s serum KPD yang diberikan anastrozol dibanding dengan yang diberikan tamoksifen (p<0,05). ... β-CrossLaps rata-rata serum KPD yang diberikan anastrozol lebih tinggi dibanding dengan tamoksifen, artinya pemberian obat anastrozol pada pasien KPD pascamenopause dalam jangka waktu >6 ... DOI: 10.15395/mkb.v47n4.615 Kata kunci: Anastrozol, β-CrossLaps serum, tamoksifen Comparison of β-crosslaps ...
Tópico(s): Breast Cancer Treatment Studies
2015 - Padjadjaran University | Majalah kedokteran Bandung/Majalah Kedokteran Bandung